Candel Therapeutics Expects To Topline Report Data From Its Phase 2 Clinical Trial Of CAN-2409 In Non-Small Cell Lung Cancer In 2Q24
Portfolio Pulse from Benzinga Newsdesk
Candel Therapeutics anticipates releasing topline report data from its Phase 2 clinical trial of CAN-2409 for non-small cell lung cancer in 2Q24.
June 13, 2023 | 12:08 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Candel Therapeutics expects to release topline data from its Phase 2 clinical trial of CAN-2409 in non-small cell lung cancer in 2Q24.
The news directly pertains to Candel Therapeutics (CADL) as it is about their Phase 2 clinical trial for CAN-2409. The impact on the stock price is neutral in the short term as the release of the data is expected in 2Q24, which is a few years away. However, the importance of the news is high as it relates to the progress of their cancer treatment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100